1. Residual Paralysis Is More Common Than You Think

2. This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

3. Introduction

4. Use of Neuromuscular Blocking Agent Improves Intubation Conditions

5. Improved Tracheal Intubation Conditions Associated With Less Laryngeal Complications Postsurgery

6. Achieving Optimal Surgical Conditions

7. Deep NMB vs No NMB

8. Dose-Dependent Relationship Between NMBAs and Postoperative Respiratory Complications

9. NMBAs and Hospital Readmission

10. NMBAs and Residual Paralysis

11. Residual NMB

12. Risk Factors Associated With Postoperative Pulmonary Complications

13. Strategies to Prevent, Reduce, and Manage Residual Paralysis

14. Does Quantitative Monitoring Lead to Decreased Risk of AEs?

15. Quantitative Monitoring Reduces Incidence of Respiratory AEs

16. Proper Monitoring: Qualitative vs Quantitative

17. Neostigmine

18. Neostigmine (cont)

19. MGH Dept. of Anesthesia and Critical Care Pain Medicine Quality Improvement Project

20. MGH DACCPM Cognitive Aid

21. Results of MGH DACCPM Quality Improvement Project

22. Sugammadex

23. Sugammadex (cont)

24. How Much Sugammadex?

25. Contraindications for Sugammadex

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)